Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Inclusion Criteria:

* Male or female patients aged over 18 years (inclusive);
* ECOG score: 0 - 2 points
* Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors, including TNBC and HNSCC
* No previous treatment with CPI
* Agreement to provide a previously archived tumor tissue specimen or biopsy to collect tumor lesion tissue
* Subject has at least 1 measurable lesion as defined by RECIST V1.1
* Expected survival ≥ 6 months
* Adequate organ function
* Males of childbearing potential or females of childbearing potential must use highly effective contraceptive methods during the trial and continuing for 6 months after the last dose
* The subject voluntarily joined the study and signed an informed consent form

Exclusion Criteria:

* Pregnant or lactating women;
* Prior cell therapy;
* Received systemic anti-tumor therapy within 2 weeks or 5 half-lives of the treatment agent (whichever is shorter) before the start of treatment;
* Previous or current presence of two or more primary tumors
* Patients with active autoimmune diseases
* Have received systemic treatment with corticosteroids (10 mg prednisone equivalent daily) or other immunosuppressive agents for more than 7 days within 2 weeks before the start of treatment
* Received investigational drugs within 2 weeks before the start of treatment;
* Major surgery or serious trauma within 4 weeks before the start of treatment;
* Patients with symptomatic central nervous system (CNS) metastasis
* Active viral infectious disease requiring systemic treatment at screening:
* Known serious hypersensitivity history
* Uncontrolled pleural effusion, ascites, or pericardial effusion at screening;
* Presence or history of active interstitial lung disease;
* Patients with hypertension that cannot be well controlled with medical therapy.
* Presence of clinically significant cardiovascular disease
* Deep venous thrombosis within 6 months before the start of treatment
* Thrombolytic therapy within 10 days prior to the start of treatment
* Any active infection requiring intravenous anti-infective therapy before the start of treatment
* Had toxicity not resolved to ≤ Grade 1 (CTCAE 5.0) from previous anticancer therapy
* Known or suspected inability to comply with the study protocol